Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue

Diagnostic Pathology

Chikao Morimoto⁴  Kei Ohnuma⁴  Nam H Dang²  Toshihiro Okamoto⁴  Eriko Komiya⁴  Hiroto Yamazaki⁴  Satoshi Iwata⁴  Shuji Matsuoka³  Taketo Yamada¹  Ryo Hatano⁴ 

[1] Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan;Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road- Box 100278, Room MSB M410A, Gainesville, FL 32610, USA;Department of Pathology & Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan;Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

关键词: T cell costimulation;    Malignant mesothelioma;    Companion diagnostic drug;    Immunohistochemical staining;    CD26/dipeptidyl peptidase 4;   

Others  :  803133
DOI  :  10.1186/1746-1596-9-30

 received in 2013-10-03, accepted in 2014-01-24,  发布年份 2014

【 摘 要 】

Background

A T cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region, CD26 is a multifunctional molecule associated with various proteins such as adenosine deaminase, caveolin-1, CXCR4, collagen, and fibronectin, while playing an important role in the regulation of inflammatory responses and tumor biology. We have focused on CD26 as a novel therapeutic target for various tumors and immune disorders, and have developed a humanized anti-CD26 monoclonal antibody (mAb), YS110, which is currently being evaluated in a phase I clinical trial for patients with CD26-expressing tumors, including malignant mesothelioma. Since detection of tumor CD26 expression is required for determining potential eligibility for YS110 therapy, the development of anti-human CD26 mAb that can clearly and reliably detect the denatured CD26 molecule in the formalin-fixed paraffin-embedded tissues is critical.

Methods

To develop novel anti-CD26 mAbs capable of binding to the denatured CD26, we immunized mice with CD26 protein denatured in urea buffer. After the fusion of splenocytes and myeloma cells, the mAbs were screened for specific reactivity with human CD26 by flow cytometry, enzyme-linked immunosorbent assay, and immunohistochemistry. The binding competitiveness of novel anti-CD26 mAbs with the humanized anti-CD26 mAb YS110 was also examined.

Results

We have succeeded in developing novel anti-human CD26 mAbs suitable for immunohistochemical staining of CD26 in formalin-fixed tissue sections with reliable clarity and intensity. Importantly, some of these mAbs exhibit no cross-reactivity with the humanized anti-CD26 mAb.

Conclusions

These novel mAbs are potentially useful as companion diagnostic agents to analyze CD26 expression in the clinical setting while advancing future CD26-related research.

Virtual slides

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5987140221097729 webcite

【 授权许可】

   
2014 Hatano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL: Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984, 133:1250-6.
• [2]Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH, Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proc Natl Acad Sci USA 1993, 90:7069-73.
• [3]Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, Dahlberg HN, Schlossman SF, Morimoto C: Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992, 149:481-6.
• [4]Morimoto C, Schlossman SF: The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998, 161:55-70.
• [5]Ohnuma K, Dang NH, Morimoto C: Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008, 29:295-301.
• [6]De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today 1999, 20:367-75.
• [7]von Bonin A, Huhn J, Fleischer B: Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol Rev 1998, 161:43-53.
• [8]Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL, Schlossman SF: 1 F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989, 143:3430-9.
• [9]Masuyama J, Yoshio T, Suzuki K, Kitagawa S, Iwamoto M, Kamimura T, Hirata D, Takeda A, Kano S, Minota S: Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999, 189:979-90.
• [10]Ohnuma K, Inoue H, Uchiyama M, Yamochi T, Hosono O, Dang NH, Morimoto C: T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 2006, 16:3-13.
• [11]Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C: CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology 2013, 138:165-72.
• [12]Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C: Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. Br J Haematol 2013, 162:263-77.
• [13]Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH: The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008, 13:1634-45.
• [14]Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, et al.: In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1 F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 2001, 7:2031-40.
• [15]Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C: Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 2006, 12:3470-7.
• [16]Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, et al.: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007, 13:4191-200.
• [17]Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C: CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 2012, 18:1447-56.
• [18]Dong RP, Tachibana K, Hegen M, Scharpe S, Cho D, Schlossman SF, Morimoto C: Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. Mol Immunol 1998, 35:13-21.
• [19]Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T: Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One 2013, 8:e62304.
• [20]Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M, Arai N: SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 1988, 8:466-72.
• [21]Tanaka J, Miwa Y, Miyoshi K, Ueno A, Inoue H: Construction of Epstein-Barr virus-based expression vector containing mini-oriP. Biochem Biophys Res Commun 1999, 264:938-43.
• [22]Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, Morimoto C: Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994, 91:3082-6.
• [23]Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H, Schlossman SF, Morimoto C: Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci USA 2000, 97:8439-44.
• [24]Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C: The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993, 90:4586-90.
• [25]Saleh HA, Jin B, Barnwell J, Alzohaili O: Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010, 5:9. BioMed Central Full Text
• [26]de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA: Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012, 7:97. BioMed Central Full Text
• [27]Hua X, Yu L, Huang X, Liao Z, Xian Q: Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol 2011, 6:111. BioMed Central Full Text
• [28]Lu Z, Qi L, Bo XJ, Liu GD, Wang JM, Li G: Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. J Res Med Sci 2013, 18:647-52.
• [29]Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H: Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008, 26:4100-8.
• [30]Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T, Sato N: Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012, 62:303-8.